213 related articles for article (PubMed ID: 32765809)
1. Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways.
Yang Y; Tian Z; Guo R; Ren F
Oxid Med Cell Longev; 2020; 2020():9867595. PubMed ID: 32765809
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
[TBL] [Abstract][Full Text] [Related]
3. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.
Olayanju A; Copple IM; Bryan HK; Edge GT; Sison RL; Wong MW; Lai ZQ; Lin ZX; Dunn K; Sanderson CM; Alghanem AF; Cross MJ; Ellis EC; Ingelman-Sundberg M; Malik HZ; Kitteringham NR; Goldring CE; Park BK
Free Radic Biol Med; 2015 Jan; 78():202-12. PubMed ID: 25445704
[TBL] [Abstract][Full Text] [Related]
4. The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers.
Tian Z; Yang Y; Wu H; Chen Y; Jia H; Zhu L; He R; Jin Y; Zhou B; Ge C; Sun Y; Yang Y
Heliyon; 2022 Aug; 8(8):e10410. PubMed ID: 36090218
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic activities of brusatol in human non-small cell lung cancer cells: Involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response.
Xie J; Lai Z; Zheng X; Liao H; Xian Y; Li Q; Wu J; Ip S; Xie Y; Chen J; Su Z; Lin Z; Yang X
Toxicology; 2021 Mar; 451():152680. PubMed ID: 33465425
[TBL] [Abstract][Full Text] [Related]
6. Brusatol: A potential sensitizing agent for cancer therapy from Brucea javanica.
He T; Zhou F; Su A; Zhang Y; Xing Z; Mi L; Li Z; Wu W
Biomed Pharmacother; 2023 Feb; 158():114134. PubMed ID: 36525821
[TBL] [Abstract][Full Text] [Related]
7. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
8. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells.
Bulut G; Atmaca H; Karaca B
Future Oncol; 2020 Jan; 16(3):4485-4495. PubMed ID: 31829029
[No Abstract] [Full Text] [Related]
10. Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
Murakami Y; Sugiyama K; Ebinuma H; Nakamoto N; Ojiro K; Chu PS; Taniki N; Saito Y; Teratani T; Koda Y; Suzuki T; Saito K; Fukasawa M; Ikeda M; Kato N; Kanai T; Saito H
BMC Cancer; 2018 Jun; 18(1):680. PubMed ID: 29940898
[TBL] [Abstract][Full Text] [Related]
11. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
12. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.
Khalil HS; Langdon SP; Goltsov A; Soininen T; Harrison DJ; Bown J; Deeni YY
Oncotarget; 2016 Nov; 7(46):75874-75901. PubMed ID: 27713148
[TBL] [Abstract][Full Text] [Related]
13. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
14. UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response.
Wang M; Shi G; Bian C; Nisar MF; Guo Y; Wu Y; Li W; Huang X; Jiang X; Bartsch JW; Ji P; Zhong JL
Oxid Med Cell Longev; 2018; 2018():9742154. PubMed ID: 29670684
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q
Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391
[TBL] [Abstract][Full Text] [Related]
17. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
18. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity.
Ding X; Gu W; Zhong Y; Hao X; Liu J; Xia S; Luo L; Chen M; Zhang C
EBioMedicine; 2020 Oct; 60():102996. PubMed ID: 32950002
[TBL] [Abstract][Full Text] [Related]
19. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract][Full Text] [Related]
20. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]